Practical Strategies for Optimizing IPF Care in Community Pulmonology Practice: A Clinician-Patient Conversation

This activity is intended for pulmonology clinicians in community practices and in interstitial lung disease (ILD) centers engaged in the care of patients with idiopathic pulmonary fibrosis (IPF).

Supported by educational grants from:

Genentech, Inc.

Activity Information


Original Release Date: December 20, 2019
Expiration Date: December 20, 2020
Estimated time to complete activity: 1.0 hour




Gregory P. Cosgrove, MD, FCCP
Associate Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, Colorado
Chief Medical Officer, Pulmonary Fibrosis Foundation
Chicago, Illinois

Kelly M. Newton, DO
TriStar Centennial Medical Center
Nashville, Tennessee

Glenda Rouland
Pulmonary Fibrosis Foundation Patient Ambassador
Birmingham, Alabama


The content of this 4-part video webcast was adapted from the proceedings of the CME-certified symposium held on October 21, 2019 at the CHEST 2019 Annual Meeting. During this webcast, expert faculty discuss strategies for the multidisciplinary diagnosis and management of Idiopathic Pulmonary Fibrosis (IPF). Individuals with IPF share their personal joruneys with the disease to illuminate gaps and successes in their care experiences and to highlight ways in which to improve communication.


Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. Although rare enough to be considered an orphan disease, IPF accounts for 15,000 to 40,000 deaths per year in the United States – and the incidence and mortality of IPF are increasing.

Despite advances in therapy, there is no cure for IPF and the prognosis of IPF is poor. Use of antifibrotic therapy may contribute to longer survival, but a substantial proportion of patients with IPF receive no pharmacologic therapy at all. Evidence and guidelines also support a multidisciplinary approach, demonstrating a need for improved interprofessional communication, collaboration, and referral. Strong clinician-patient communication helps patients understand their disease, improves accuracy of diagnosis, and contributes to greater patient recognition of their role in IPF disease management.


At the conclusion of this activity, participants should be better able to:

  • Identify the degree of impact of IPF on patients’ quality of life.
  • Describe the benefits of multidisciplinary care for IPF and the reasons for these benefits.
  • Engage a multidisciplinary care team to treat patients with IPF, by referral or collaboration.
  • Select appropriate pharmacologic and non-pharmacologic therapy and manage adverse events.
  • Demonstrate communication techniques for use with IPF patients that include effective disease-state and disease-management education, as well as support services available to them.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designed for .05 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Name of Faculty or Presenter Reported Financial Relationship

Name of Faculty or Presenter
Gregory P. Cosgrove, MD

Reported Financial Relationship
Royalty: New Aera
Consulting: Boehringer Ingelheim
Contracted Research: Genentech, Boehringer Ingelheim, Global Blood Therapeutics

Name of Faculty or Presenter
Kelly M. Newton, DO

Reported Financial Relationship
Nothing to disclose

Name of Faculty or Presenter
Glenda Rouland

Reported Financial Relationship
Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Global Academy for Medical Education planners and managers have nothing to disclose.


There are no fees for participating and receiving CME/CE credit for this activity. During the period December 20, 2019 through December 20, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation at or On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14762. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. 


Internet Activity


Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.